Literature DB >> 10823292

Does increasing dose improve efficacy in patients with poor antidepressant response: a review.

E Corruble1, J D Guelfi.   

Abstract

OBJECTIVE: Therapeutic strategies in depressed patients with no or partial response to adequate first-line antidepressant medication remain a matter of concern. This paper focuses on the strategy of dose increase.
METHOD: This review was based on a systematic Medline search of papers dealing with antidepressant dose issues in major depression since the 1960s.
RESULTS: The strategy of dose increase is poorly studied in clinical trials.
CONCLUSION: Until this strategy is better studied, caution is advised in its use. However, antidepressants for which this strategy seems to be the most relevant are tricyclic drugs and serotonin and noradrenaline reuptake inhibitors. These results are discussed both in terms of therapeutic strategies for the clinician and in terms of clinical research.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10823292     DOI: 10.1034/j.1600-0447.2000.101005343.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  8 in total

1.  When common clinical practice meets evidence-based medicine.

Authors:  David Feifel
Journal:  Psychiatry (Edgmont)       Date:  2006-12

Review 2.  Tolerability of selective serotonin reuptake inhibitors: issues relevant to the elderly.

Authors:  Brian Draper; Karen Berman
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

3.  Pretreatment Reward Sensitivity and Frontostriatal Resting-State Functional Connectivity Are Associated With Response to Bupropion After Sertraline Nonresponse.

Authors:  Yuen-Siang Ang; Roselinde Kaiser; Thilo Deckersbach; Jorge Almeida; Mary L Phillips; Henry W Chase; Christian A Webb; Ramin Parsey; Maurizio Fava; Patrick McGrath; Myrna Weissman; Phil Adams; Patricia Deldin; Maria A Oquendo; Melvin G McInnis; Thomas Carmody; Gerard Bruder; Crystal M Cooper; Cherise R Chin Fatt; Madhukar H Trivedi; Diego A Pizzagalli
Journal:  Biol Psychiatry       Date:  2020-04-23       Impact factor: 13.382

4.  Reviewing long-term antidepressants can reduce drug burden: a prospective observational cohort study.

Authors:  Chris F Johnson; Hector J Macdonald; Pauline Atkinson; Alasdair I Buchanan; Noreen Downes; Nadine Dougall
Journal:  Br J Gen Pract       Date:  2012-11       Impact factor: 5.386

Review 5.  Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review.

Authors:  Mazda Adli; Christopher Baethge; Andreas Heinz; Nicolas Langlitz; Michael Bauer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-04-29       Impact factor: 5.760

6.  Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocol.

Authors:  Toshi A Furukawa; Tatsuo Akechi; Shinji Shimodera; Mitsuhiko Yamada; Kazuhira Miki; Norio Watanabe; Masatoshi Inagaki; Naohiro Yonemoto
Journal:  Trials       Date:  2011-05-11       Impact factor: 2.279

7.  Patient factors associated with SSRI dose for depression treatment in general practice: a primary care cross sectional study.

Authors:  Chris F Johnson; Nadine J Dougall; Brian Williams; Stephen A MacGillivray; Alasdair I Buchanan; Richard D Hassett
Journal:  BMC Fam Pract       Date:  2014-12-24       Impact factor: 2.497

8.  Optimising first- and second-line treatment strategies for untreated major depressive disorder - the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial.

Authors:  Tadashi Kato; Toshi A Furukawa; Akio Mantani; Ken'ichi Kurata; Hajime Kubouchi; Susumu Hirota; Hirotoshi Sato; Kazuyuki Sugishita; Bun Chino; Kahori Itoh; Yoshio Ikeda; Yoshihiro Shinagawa; Masaki Kondo; Yasumasa Okamoto; Hirokazu Fujita; Motomu Suga; Shingo Yasumoto; Naohisa Tsujino; Takeshi Inoue; Noboru Fujise; Tatsuo Akechi; Mitsuhiko Yamada; Shinji Shimodera; Norio Watanabe; Masatoshi Inagaki; Kazuhira Miki; Yusuke Ogawa; Nozomi Takeshima; Yu Hayasaka; Aran Tajika; Kiyomi Shinohara; Naohiro Yonemoto; Shiro Tanaka; Qi Zhou; Gordon H Guyatt
Journal:  BMC Med       Date:  2018-07-11       Impact factor: 8.775

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.